Literature DB >> 19389491

Acute transverse myelitis: a practical reappraisal.

Maria José Sá1.   

Abstract

Acute transverse myelitis (ATM), a subgroup of various conditions that cause transverse spinal cord syndromes, is an inflammatory and usually idiopathic spinal cord disease. Idiopathic ATM is diagnosed according to established criteria which mainly assure a clinical picture of bilateral symptoms and signs attributable to spinal cord disease, existence of focal cord inflammation by magnetic resonance imaging and cerebrospinal fluid studies, and exclusion of many diseases, especially cord compression and "disease-associated ATM", as Sjögren disease. Patients with idiopathic ATM have motor, sensory and autonomic dysfunctions with acute or subacute onset, progressing to nadir in 4 h to 21 days, with full or partial recovery in most cases. Emergent treatment to halt inflammation with corticosteroids is required as well as early appropriate symptomatic therapies. Recent discovery of novel biomarkers has set apart specific inflammatory and autoimmune myelopathies, namely paraneoplastic myelitis and neuromyelitis optica spectrum diseases, the diagnosis of which is crucial to establish therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19389491     DOI: 10.1016/j.autrev.2009.04.005

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  14 in total

1.  Recurrent myelitis in common variable immunodeficiency successfully managed with high-dose subcutaneous immunoglobulin.

Authors:  Maria Giovanna Danieli; Lucia Pettinari; Lucia Marinangeli; Francesco Logullo
Journal:  BMJ Case Rep       Date:  2012-08-08

2.  Relief of Neuropathic Pain After Spinal Cord Stimulator Implantation in a Patient With Idiopathic Thoracic Transverse Myelitis: A Case Report.

Authors:  Rajiv Reddy; Rupa Prasad; Sepehr Rejai; Kenneth Halter; Jeffrey Chen
Journal:  A A Pract       Date:  2019-12-01

3.  Advantages of multiplex proteomics in clinical immunology: the case of rheumatoid arthritis: novel IgXPLEX™: planar microarray diagnosis.

Authors:  Peter Lea; Edward Keystone; Sasi Mudumba; Anthony Kahama; Shi-Fa Ding; Jennifer Hansen; Azar A Azad; Sihe Wang; Deborah Weber
Journal:  Clin Rev Allergy Immunol       Date:  2011-08       Impact factor: 8.667

4.  Spectrum of nontraumatic myelopathies in Ethiopian patients: hospital-based retrospective study.

Authors:  N J Fidèle; A Amanuel
Journal:  Spinal Cord       Date:  2015-12-29       Impact factor: 2.772

5.  Comparisons of presentations and outcomes of neuromyelitis optica patients with and without Sjögren's syndrome.

Authors:  Yu Hua Zhong; Zhi Gang Zhong; Zhou Zhou; Zhen Yu Ma; Meng Yao Qiu; Fu Hua Peng; Wei Xi Zhang
Journal:  Neurol Sci       Date:  2016-11-05       Impact factor: 3.307

Review 6.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

7.  Symptomatic noncompressive motoromyelopathy presents as early manifestation in ankylosing spondylitis.

Authors:  Wei-Hsi Chen; Hsin-Ling Yin; Hung-Sheng Lin; Chung-Jen Chen
Journal:  Rheumatol Int       Date:  2010-11-02       Impact factor: 3.580

Review 8.  Sjögren's syndrome and neuromyelitis optica spectrum disorders (NMOSD)--a case report and review of literature.

Authors:  Apoorva Jayarangaiah; Rahul Sehgal; Narendranath Epperla
Journal:  BMC Neurol       Date:  2014-10-09       Impact factor: 2.474

9.  Acute Transverse Myelitis Associated with Buserelin Use during IVF.

Authors:  Djavid I Alleemudder; Khaled Sadek; Shaun Fountain; Sallie Davies
Journal:  Case Rep Obstet Gynecol       Date:  2013-03-28

10.  Acute transverse myelitis of the cervical spine secondary to psoas abscess.

Authors:  Hongyu He; Lirong Jin; Minjie Ju; Guowei Tu; Zhe Luo
Journal:  BMC Infect Dis       Date:  2016-10-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.